Accelerating Biopharma 'Go Global' in Southeast Asia: Strategies

On September 9th, the Chinese Businessmen Going Global Industry Service Alliance was officially established.

This is a one-stop community for going global, initiated by Wu Xiaobo Channel in conjunction with industry service organizations for going global, welcoming entrepreneurs and service providers to join the alliance.

In 2024, among the hot topics that entrepreneurs are concerned about, "going global" is undoubtedly a focus that cannot be ignored.

Following the hosting of the first Global Going Global Summit with the theme "Born Global, Determined Future" in Singapore, the 2024 Going Global Summit focusing on the supply chain in Xiamen, and the New Zhejiang Businessmen Globalization Layout Forum in Hangzhou, we have shifted our focus to the going global of enterprises in the biopharmaceutical field.

On September 27th, the Chinese Businessmen Going Global Industry Service Alliance will collaborate with the 9th "Maker China" Biopharmaceutical SME Innovation and Entrepreneurship Competition to hold the "Born Global" Biopharmaceutical Innovation Going Global Forum in Guangzhou Nansha.

If you are a related enterprise, you are welcome to join us in discussing the challenges and opportunities of globalization, how Chinese biopharmaceutical enterprises can better integrate into the international market, and achieve the global application and commercialization of innovative results.

Going global has become the most important proposition in the medical industry at present.

In fact, the trend of going global has been emerging since 2023.

The first to enter people's field of vision is the going global of innovative drugs.

In October 2023, Hengrui Medical announced that it had reached an exclusive licensing agreement with German Merck for its independently developed PARP1 inhibitor HRS-1167.

According to the terms of the agreement, Hengrui will receive up to 1.4 billion euros.

Real orders have allowed the "internal volume" domestic biopharmaceutical industry to turn its attention to the vast global market.

By 2024, the hot momentum of domestic innovative drugs going global continues.

According to data from Meibai Capital, in January 2024, there were a total of 18 license out transactions by Chinese pharmaceutical companies, a 260% increase from the 5 transactions in January 2023.

At the same time, the spark of going global has also spread from innovative drugs to the medical device track.

Taking the IVD (in vitro diagnosis) industry as an example, it is a market of hundreds of billions of yuan in China, and a market of hundreds of billions of dollars globally.

Looking at the growth history of international pharmaceutical giants, it is not difficult to find that entering the global market is an inevitable path for development, and the international market is the necessary foundation for supporting enterprises to grow.

However, the path of biopharmaceutical enterprises going global is by no means smooth sailing.

The first is the patent monopoly and technological innovation of international giants.

Although innovative pharmaceutical companies have achieved significant results in going global, in recent years, there have also been quite a few news of being returned.

Compared with European and American giants, Chinese biopharmaceutical companies still have a big gap in aspects such as technology research and development, channel layout, etc.

Secondly, it is the difficulty of laws and regulations.

Due to the particularity of pharmaceutical products, the policies and regulations of the destination, communication with local drug regulatory agencies, sorting out import and export processes, document preparation, local language, time difference, etc., are great challenges for Chinese enterprises.

In addition, there are other risks, such as international geopolitical issues, trade protectionism, and safety issues in some emerging markets, all of which are tests for biopharmaceutical enterprises going global.

So, how can biopharmaceutical enterprises overcome challenges on the road to going global, and what pioneers can we learn from?

Welcome entrepreneurs and entrepreneurs to register to participate in the "Born Global" Biopharmaceutical Innovation Going Global Forum held in Guangzhou on September 27th.

At this "Born Global" Biopharmaceutical Innovation Going Global Forum, we have invited macroeconomic research scholars, senior investors in the biopharmaceutical field, and well-known leaders of going global enterprises to discuss the strategic layout, innovative path, and future development direction of Chinese biopharmaceutical enterprises going global.

◎ Observing trends, this forum has invited Dr. Wei Hongxu from the Macroeconomic Research Center of Anbang Think Tank to give a keynote speech on the macro trend of Chinese enterprises going global.

As a global economic research scholar, Mr. Wei will analyze the current international situation and economic development trends, helping enterprises going global to see the future direction from a higher dimension.

◎ Debating the direction, the biopharmaceutical industry has a large investment in early-stage research and development, especially when new drugs go global, overseas clinical trials have almost become a must, and their costs are generally 3 to 5 times that of domestic clinical trials, which increases the demand for capital.

In terms of capital direction, the forum will also invite well-known investors in the biopharmaceutical field to share the hot spots and trends seen by capital with everyone.

◎ Talking about experience, when Mr. Wu Xiaobo talked about enterprises going global, he once said, "Chinese help Chinese, everything can be done."

In this round of enterprises going global, facing the vast but unfamiliar overseas market, Chinese enterprises need to learn from each other, communicate with each other, and huddle together for warmth.

The forum has invited the actual leaders of well-known enterprises going global to share their precious "actions" and "thoughts" in exploring going global.

◎ Looking at data, in addition to Europe and America, the Southeast Asian region is also a hot choice for biopharmaceutical enterprises going global.

According to the MRII International Market Research Institute, from 2023 to 2027, the average annual compound growth rate of the pharmaceutical market in emerging countries represented by Southeast Asian countries will remain at 5%-8%, higher than the 2.5%-5.5% of developed markets.

At this forum, Zhuo Li, the executive dean of Jida Business School, will also interpret the "Going Global Southeast Asia Research Report" and clarify the development opportunities of ASEAN countries with participating enterprises.

There are big fish in the sea.

In the field of biopharmaceuticals, "going global" has become a proposition that enterprises must think about, but how to go global safely and efficiently is still unknown for Chinese enterprises to explore.

Facing the surging international market, while everyone is sorting out their own luggage, you are also welcome to come to this "Born Global" Biopharmaceutical Innovation Going Global Forum.

Let's look up at the sky together and discuss the direction and experience of the road ahead.